Get started
Author

Takahiro Inoue

Observed institution: Asahikawa Medical University
ORCID: 0009-0006-2457-9063
Observed ORCID: 0009-0006-2457-9063
OpenAlex ID: A5112489998
Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2
2024 · Ryosuke Sato, Hiroki Komatsuda, et al. · Head & Neck · 8
PDF
Tumor-promoting function of paternally expressed gene 10 and its immunogenicity in inducing anti-tumor helper T cells in head and neck squamous cell carcinoma
2025 · Hiroki Komatsuda, Toshihiro Nagato, et al. · Cancer Immunology Immunotherapy · 2
PDF
Cerebral Infarction as a Rare Adverse Event of Immune Checkpoint Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma: A Case Series
2023 · Takahiro Inoue, Takumi Kumai, et al. · Cureus · 2
PDF
A Current-Mode Analog BiCMOS Multiplier/Divider Circuit Based on the Translinear Principle
1996 · Kyoko Tsukano, Takahiro Inoue, et al. · IEICE Transactions on Fundamentals of Electronics Communications and Computer Sciences · 1
Design of New Fuzzy Operational Analog Integrated Circuits Using OTAs
1991 · Tetsuo Motomura, Takahiro Inoue, et al. · IEEE International Symposium on Circuits and Systems proceedings · 1
Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy
2026 · Ryosuke Sato, Shota Sakaue, et al. · Cancer Immunology Immunotherapy
Data from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 4 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 3 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Table 2 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Table 1 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Supplemental Figure 5 from Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al.
Peptide-Reactive T-cell Response as a Novel Biomarker in Patients with Head and Neck Cancer Treated with Anti–PD-1 Antibody
2026 · Takumi Kumai, Shota Sakaue, et al. · Cancer Research Communications
Basic and Clinical Evidence for Perioperative Immunotherapy in Resectable HNSCC
2026 · Shota Sakaue, Michihisa Kono, et al. · Cancers
PDF
Bovine Lactoferrin Modulates Mononuclear Cell Activity in Human Palatine Tonsils
2026 · Takumi Yago, Chisane Kujirai, et al. · International Journal of Molecular Sciences
PDF
ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma
2025 · Ryosuke Sato, Hidekiyo Yamaki, et al. · Cancers
PDF
An Unresectable Eyelid Squamous Cell Carcinoma Treated With Concurrent Chemoradiation Therapy
2025 · Kenzo Ohara, Yuto Izumiya, et al. · Cureus
Su1804 PRETREATMENT LEVELS OF SERUM LEUCINE-RICH ALPHA-2 GLYCOPROTEIN IS USEFUL FOR SELECTION OF ANTI-CYTOKINE BIOLOGICS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTICENTER PROSPECTIVE COHORT STUDY BY THE OSAKA GUT FORUM
2024 · Satoshi Hiyama, Takahiro Amano, et al. · Gastroenterology
Works count: 32
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type